Nitrogen-13 is a radioisotope used in positron emission tomography (PET). It has a half-life of 9.9 minutes. 13N is mainly used and labelled Ammonia for PET myocardial perfusion imaging (MPI) but it can also be used for brain and liver imaging.
Cyclone® KIUBE
To maximize the production of 13N while limiting the production of impurities, the protons need to reach the target around 16MeV, the target is equipped with a degrader foil to reach the optimum energy.
Nirta® Liquid target
The irradiation of the purified water with an ethanol scavenger via 16O (p,alpha) 13N nuclear reaction produces ‘in-target’ [13N]NH3(ammonia).
In-target production
See information in the target section.
Cyclone® KEY
N-13 is produced at 9.2 MeV.
IBA developed a fully automated solution for the production of N-13- Ammonia; AKURACY®. This solution can produce and deliver a dose every 10 min next to your PET camera.
Nirta® Liquid target
The irradiation of the purified water with an ethanol scavenger via 16O (p,alpha) 13N nuclear reaction produces ‘in-target’ [13N]NH3(ammonia).
Synthera® +
See information in the target section.
Cyclone® IKON
13N can also be produced on the Cyclone® IKON with its variable energy.
Nirta® Liquid target
The irradiation of the purified water with an ethanol scavenger via 16O (p,alpha) 13N nuclear reaction produces ‘in-target’ [13N]NH3(ammonia).
In-target production
See information in the target section.
Gameiro1, Cristiana; Bormans2, Guy; Abrunhosa3, Antero; 4Luurtsema, G. and Elsinga4,Philip
1 IBA-Ion Beam applications SA/BE; 2 PET Center, University of Leuven/BE; 3 ICNAS, University of Coimbra/PT; 4 Medical Imaging Centre, University of Groningen/NL.
S. Chana, D. Cryera, A.H. Asada,b, R.I. Pricea,c a Department of Medical Technology and Physics, Sir Charles Gairdner Hospital, Perth, Western Australia b Imaging & Applied Physics, Curtin University, Western Australia c School of Physics, University of Western Australia, Western Australia
Faisal Alrumayan, F. Oberdorferb, Q. Akkam, J. Schneider, S. Alyanbawi and I. Al-Jammaz
P. Vlottes*1, F. Devillet2, M. Ghyoot2, R. Knol1, E. Mooij1 1MCA (medisch centrum alkmaar), Alkmaar, The Netherlands; 2 IBA RadioPharma Solution, Louvain-la-Neuve, Belgium
M Auger, S Braccini, A Ereditato, K P Nesteruk and P Scampoli